6 unknown, 4 completed, 3 terminated, 1 not yet recruiting. 15 Phase 3, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 15 | Unknown 6, Completed 4, Terminated 3, Not yet recruiting 1, Withdrawn 1 |
| Phase 2 | 8 | Unknown 5, Terminated 2, Completed 1 |
Follow Covid 19: new trials by email Literature Review of Covid 19 trials Research Report on Covid 19
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and Influenza Nitazoxanide 600Mg Oral Tablet / placebo oral tablet - Covid 19, Influenza | Phase 3 | Not yet recruiting | Azidus Brasil | 340 | 2025-02-01 | 2025-02-10 |
| Allogenic UCMSCs as Adjuvant Therapy for Severe COVID-19 Patients Normoxic Allogenic UCMSC, Normal saline solution - Covid 19 | Phase 2 / Phase 3 | Unknown | Kementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, Indonesia | 42 | 2021-01-17 | 2021-11-24 |
| Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 Linagliptin 5 MG - COVID 19, Coronavirus | Phase 3 | Terminated | Rabin Medical Center | 64 | 2020-10-01 | 2021-06-02 |
| Inhaled Ciclesonide for Outpatients With COVID19 Normal Saline intranasal and placebo inhaler, Ciclesonide, Ciclesonide nasal - COVID 19 | Phase 2 / Phase 3 | Terminated | McGill University Health Centre/Research Institute of the McGill University Health Centre | 215 | 2020-09-15 | 2022-06-10 |
| CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION MR or M-M-R II ® vaccine, Placebo - COVID 19 | Phase 3 | Completed | Washington University School of Medicine | 3411 | 2020-09-04 | 2024-03-26 |
| Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia Almitrine, Placebo - Covid 19, Hypoxemic Respiratory Failure | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 181 | 2020-09-03 | 2022-05-03 |
| Post Exposure Prophylaxis in Healthcare Workers Exposed to COVID-19 Patients Hydroxychloroquine - COVID 19 | Phase 2 / Phase 3 | Unknown | Hamad Medical Corporation | 500 | 2020-08-31 | 2020-08-11 |
| Potential Role of Gum Arabic as Immunomodulatory Agent Among COVID 19 Patients Acacia Senegal, Pectin - COVID 19 | Phase 2 / Phase 3 | Unknown | Al-Neelain University | 110 | 2020-06-01 | 2020-05-12 |
| BromhexIne And Spironolactone For CoronаVirUs Infection Requiring HospiTalization Bromhexine and Spironolactone, Base therapy - COVID 19 | Phase 3 | Unknown | Lomonosov Moscow State University Medical Research and Educational Center | 80 | 2020-05-16 | 2020-06-09 |
| Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia HCQ, Azithromycin, Doxycycline - COVID 19, Patients Hospitalized | Phase 3 | Withdrawn | Abderrahmane Mami Hospital | 2020-05-15 | 2020-08-27 | |
| Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT Hydroxychloroquine, Oseltamivir, Azithromycin - COVID 19 | Phase 3 | Completed | Shehnoor Azhar | 550 | 2020-04-22 | 2022-02-10 |
| Trial of Hydroxychloroquine In Covid-19 Kinetics Hydroxychloroquine, Placebo - Covid 19, Corona Virus Infection | Phase 2 / Phase 3 | Terminated | University of South Alabama | 3 | 2020-04-17 | 2022-01-03 |
| Oral 25-hydroxyvitamin D3 and COVID-19 Oral 25-Hydroxyvitamin D3 - COVID 19 | Phase 2 / Phase 3 | Unknown | Tehran University of Medical Sciences | 1500 | 2020-04-14 | 2020-06-12 |
| The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients Hydroxychloroquine, Remdesivir, (Standard of Care) SoC - SARS-CoV Infection, COVID 19 | Phase 2 / Phase 3 | Unknown | Oslo University Hospital | 700 | 2020-03-28 | 2020-04-14 |
| Pirfenidone LP or Collagen-polyvinylpyrrolidone in COVID-19 Collagen-polyvinylpyrrolidone, Pirfenidone 1200 mg - COVID 19 | Phase 2 / Phase 3 | Completed | Materno-Perinatal Hospital of the State of Mexico | 36 | 2020-02-01 | 2024-09-05 |
COVID-19 (15) · Coronavirus Infections (2) · Cytokine Release Syndrome (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1) · Influenza, Human (1) · Metabolic Diseases (1) · Respiratory Insufficiency (1) · Respiratory Tract Diseases (1) · Severe Acute Respiratory Syndrome (1) · Virus Diseases (1)
Coronaviridae Infections (15) · Infections (15) · Lung Diseases (15) · Nidovirales Infections (15) · Pneumonia (15) · Pneumonia, Viral (15) · RNA Virus Infections (15) · Respiratory Tract Infections (15) · Respiratory Tract Diseases (14) · Virus Diseases (14) · Coronavirus Infections (13) · Inflammation (1) · Nutritional and Metabolic Diseases (1) · Orthomyxoviridae Infections (1) · Pathologic Processes (1)
Hydroxychloroquine (4) · Azithromycin (2) · Almitrine (1) · Bromhexine (1) · Calcifediol (1) · Doxycycline (1) · Gum Arabic (1) · Linagliptin (1) · Oseltamivir (1) · Pectins (1) · Saline Solution (1) · Spironolactone (1) · Standard of Care (1) · Tablets (1) · Zinc (1)
Abderrahmane Mami Hospital (1) · Al-Neelain University (1) · Assistance Publique - Hôpitaux de Paris (1) · Azidus Brasil (1) · Hamad Medical Corporation (1) · Kementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, Indonesia (1) · Lomonosov Moscow State University Medical Research and Educational Center (1) · Materno-Perinatal Hospital of the State of Mexico (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · Oslo University Hospital (1) · Rabin Medical Center (1) · Shehnoor Azhar (1) · Tehran University of Medical Sciences (1) · University of South Alabama (1) · Washington University School of Medicine (1)
United States (2) · Canada (1) · France (1) · Ghana (1) · Indonesia (1) · Iran (1) · Israel (1) · Mexico (1) · Norway (1) · Pakistan (1) · Russia (1) · South Africa (1) · Sudan (1) · Tunisia (1) · United Kingdom (1)
Ahmad Faried, Prof. MD (1) · Andreas Barratt-Due, MD, PhD (1) · Anne Margarita Dyrhol Riise, MD, Professor (1) · Arash Shirvani, MD, PhD (1) · Arief Nurudin, MD PhD (1) · Helen Rees, MD (1) · Inge Christoffer Olsen, PhD (1) · Javed Akram, FRCP (1) · Katerina Nezvalova-Henriksen, Pharm D, PhD (1) · Michael F Holick, PhD,MD (1) · Michael S. Avidan, MBBCh (1) · Moawia M Mukhtar, PhD (1) · Mohamadali Sahraian, MD (1)
PMID 29859173, PMID 32085846, PMID 32214286, PMID 32265310, PMID 32281062, PMID 32756149, PMID 32771032, PMID 32891160, PMID 33757717, PMID 34251903, PMID 34350582, PMID 34473343, PMID 34728476, PMID 35002970, PMID 35713300, PMID 35799756, PMID 35876699, PMID 36157895, PMID 36695483, PMID 37153751, PMID 38827854, PMID 39533001, PMID 41035643